Kunze Annett, Huwyler Jörg, Camenisch Gian, Poller Birk
Division of Drug Metabolism and Pharmacokinetics, Drug-Drug Interactions Section, Novartis Institutes for BioMedical Research, Basel, Switzerland (A.K., G.C., B.P.); and Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland (A.K., J.H.).
Division of Drug Metabolism and Pharmacokinetics, Drug-Drug Interactions Section, Novartis Institutes for BioMedical Research, Basel, Switzerland (A.K., G.C., B.P.); and Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland (A.K., J.H.)
Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.
Organic anion-transporting polypeptides (OATP) 1B1 and OATP1B3 are drug transporters mediating the active hepatic uptake of their substrates. Because they exhibit overlapping substrate specificities, the contribution of each isoform to the net hepatic uptake needs to be considered when predicting drug-drug interactions. The relative contribution of OATP1B1- and OATP1B3-mediated uptake of statins into hepatocytes was estimated based on either relative transporter protein expression data or relative activity data. Therefore, kinetics of eight statins and OATP1B1- and OATP1B3-specific reference substrates was determined in OATP1B1- and OATP1B3-expressing human embryonic kidney 293 cells and in human cryopreserved hepatocytes. Absolute OATP1B1 and OATP1B3 protein abundance was determined by liquid chromatography-tandem mass spectrometry in all expression systems. Transporter activity data generated in recombinant cell lines were extrapolated to hepatocyte values using relative transporter expression factors (REF) or relative activity factors (RAF). Our results showed a pronounced OATP1B1 and comparatively low OATP1B3 protein expression in the investigated hepatocyte lot. Based on REF scaling, we demonstrated that the active hepatic uptake clearances of reference substrates, atorvastatin, pravastatin, rosuvastatin, and simvastatin were well predicted within twofold error, demonstrating that OATP1B1 and OATP1B3 were major contributors. For other statins, the net hepatic uptake clearance was underpredicted, suggesting the involvement of other hepatic uptake transporters. Summarized, we showed that REF- and RAF-based predictions were highly similar, indicating a direct transporter expression-activity relationship. Moreover, we demonstrated that the REF-scaling method provided a powerful tool to quantitatively assess the transporter-specific contributions to the net uptake clearance of statins in hepatocytes.
有机阴离子转运多肽(OATP)1B1和OATP1B3是介导其底物肝脏主动摄取的药物转运体。由于它们表现出重叠的底物特异性,在预测药物相互作用时,需要考虑每种异构体对肝脏净摄取的贡献。基于转运体蛋白相对表达数据或相对活性数据,估算了OATP1B1和OATP1B3介导他汀类药物摄取进入肝细胞的相对贡献。因此,在表达OATP1B1和OATP1B3的人胚肾293细胞以及人冷冻保存肝细胞中,测定了8种他汀类药物以及OATP1B1和OATP1B3特异性参考底物的动力学。通过液相色谱 - 串联质谱法测定所有表达系统中OATP1B1和OATP1B3的绝对蛋白丰度。使用相对转运体表达因子(REF)或相对活性因子(RAF),将重组细胞系中产生的转运体活性数据外推至肝细胞值。我们的结果显示,在所研究的肝细胞批次中,OATP1B1蛋白表达显著,而OATP1B3蛋白表达相对较低。基于REF标度,我们证明参考底物阿托伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀的肝脏主动摄取清除率在两倍误差范围内得到了很好的预测,表明OATP1B1和OATP1B3是主要贡献者。对于其他他汀类药物,肝脏净摄取清除率预测不足,提示其他肝脏摄取转运体的参与。总之,我们表明基于REF和RAF的预测高度相似,表明转运体表达与活性之间存在直接关系。此外,我们证明REF标度法为定量评估转运体对肝细胞中他汀类药物净摄取清除率的特异性贡献提供了有力工具。